In a 2018 study, the MEK1/2 inhibitors U0126, PD901, and Selumetinib were shown to significantly reduce ERK1/2 phosphorylation, thereby suppressing the proliferation of iCCA cells in vitro [109]. This evidence concerns the gene MAPK3 and infantile convulsions and choreoathetosis.